Search

Displaying results 1221 - 1230 of 4004 in total
  1. Drug

    Conivaptan

    go.drugbank.com/drugs/DB00872
    Approved

    Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin).

  2. Drug

    Clomipramine

    go.drugbank.com/drugs/DB01242
    ApprovedInvestigationalVet approved

    They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. … In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake.

    Categories: Non-Selective Monoamine Reuptake Inhibitors
  3. Drug

    Motixafortide

    go.drugbank.com/drugs/DB14939
    ApprovedInvestigational

    [L48136] Similar in mechanism to the previously approved [plerixafor], motixafortide is an inhibitor of C-X-C Motif Chemokine Receptor 4 (CXCR4), a protein that helps to anchor stem cells to bone marrow

  4. Drug

    Sodium phosphate, dibasic

    go.drugbank.com/drugs/DB14502
    ApprovedInvestigational

    Mixtures: SOLUZIONE POLISALINICA CONCENTRATA CON POTASSIO MONICO, SOLUZIONE POLISALINICA CONCENTRATA CON POTASSIO MONICO
  5. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    This approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791] … [A262097] On November 8th, 2023, fruquintinib was approved by the FDA under the brand name Fruzaqla for the treatment of adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine

  6. Drug

    Sodium cellulose phosphate

    go.drugbank.com/drugs/DB06776
    Approved

    [A31694] This compound is an ion-exchange resin that can not be absorbed by the body. However, it can be used to restore normal intestinal calcium absorption.

  7. Drug

    Tafamidis

    go.drugbank.com/drugs/DB11644
    ApprovedInvestigational

    [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]

  8. Drug

    Olezarsen

    go.drugbank.com/drugs/DB18728
    ApprovedInvestigational

    [L52033] On December 19, 2024, olezarsen was approved by the FDA for the treatment of familial chylomicronemia syndrome.[L52028] It is also being investigated for the treatment of hyperlipidemia.

    Categories: Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  9. Drug

    Avanafil

    go.drugbank.com/drugs/DB06237
    Approved

    [L32113] It first received FDA approval on April 27, 2012,[L32058] with subsequent EMA approval in June 2013.[L32113]

  10. Drug

    Evening primrose oil

    go.drugbank.com/drugs/DB11358
    ApprovedNutraceutical

    [A33131] Evening primrose oil has been filled for the FDA by Humanetics Corporation on April 2000 to be a new dietary ingredient but its current status is "Inadequate basis for expectation of safety".